GlobeNewswire: Achillion Pharmaceuticals, Inc. Contains the last 10 of 292 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T04:12:43ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/12/19/1962874/0/en/Achillion-Shareholders-Approve-Agreement-to-be-Acquired-by-Alexion.html?f=22&fvtc=4&fvtv=6763Achillion Shareholders Approve Agreement to be Acquired by Alexion2019-12-19T14:24:06Z<![CDATA[BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.]]>https://www.globenewswire.com/news-release/2019/12/09/1958002/0/en/Achillion-Reports-Positive-Data-from-Phase-2-Study-of-Danicopan-ACH-4471-in-Combination-with-Eculizumab-in-PNH-Patients-who-Have-an-Inadequate-Response-to-Eculizumab-Monotherapy-at.html?f=22&fvtc=4&fvtv=6763Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting2019-12-09T15:00:00Z<![CDATA[– 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 -]]>https://www.globenewswire.com/news-release/2019/11/19/1949350/0/en/European-Medicines-Agency-Grants-PRIME-Designation-to-Danicopan-for-Treatment-of-Paroxysmal-Nocturnal-Hemoglobinuria-Patients-Who-Are-Not-Adequately-Responding-to-a-C5-Inhibitor.html?f=22&fvtc=4&fvtv=6763European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor2019-11-19T12:30:00Z<![CDATA[– Phase 3 PNH initiation planned early 2020 – – Phase 3 PNH initiation planned early 2020 –]]>https://www.globenewswire.com/news-release/2019/11/11/1944656/0/en/Achillion-Announces-Clearance-of-Investigational-New-Drug-Application-for-ACH-5228.html?f=22&fvtc=4&fvtv=6763Achillion Announces Clearance of Investigational New Drug Application for ACH-52282019-11-11T12:30:00Z<![CDATA[BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug Application (IND) for ACH-5228, the Company’s second-generation oral factor D inhibitor. The opening IND study in the United States will be a drug-drug interaction study with ACH-5228. The Company expects to begin a Phase 2 proof-of-concept paroxysmal nocturnal hemoglobinuria (PNH) clinical trial of ACH-5228 in the first half of 2020.]]>https://www.globenewswire.com/news-release/2019/11/07/1943044/0/en/Achillion-Reports-Third-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=6763Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update2019-11-07T12:30:00Z<![CDATA[– Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 –]]>https://www.globenewswire.com/news-release/2019/11/06/1942282/0/en/Achillion-Announces-Data-Presentations-at-the-61st-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=6763Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting2019-11-06T14:07:20Z<![CDATA[BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the acceptance of two abstracts about danicopan, the Company’s lead oral factor D inhibitor, for poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 7-10, 2019.]]>https://www.globenewswire.com/news-release/2019/09/26/1921267/0/en/Achillion-to-Present-at-the-2019-Cantor-Fitzgerald-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=6763 Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference2019-09-26T12:32:36Z<![CDATA[BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019, at 8:55 a.m. ET at the InterContinental New York Barclay in New York, NY.]]>https://www.globenewswire.com/news-release/2019/09/25/1920498/0/en/Achillion-Receives-Breakthrough-Therapy-Designation-from-FDA-for-Danicopan-for-Treatment-of-Paroxysmal-Nocturnal-Hemoglobinuria.html?f=22&fvtc=4&fvtv=6763Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria2019-09-25T11:00:00Z<![CDATA[– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 –]]>https://www.globenewswire.com/news-release/2019/08/29/1908758/0/en/Achillion-to-Present-at-the-Baird-2019-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=6763Achillion to Present at the Baird 2019 Global Healthcare Conference2019-08-29T21:00:00Z<![CDATA[BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the Baird 2019 Global Healthcare Conference on Thursday, September 5, 2019, at 12:50 p.m. ET at the InterContinental New York Barclay in New York, NY.]]>https://www.globenewswire.com/news-release/2019/08/08/1899125/0/en/Achillion-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=6763Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update2019-08-08T11:30:00Z<![CDATA[– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA –]]>